A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Functional Constipation in Children Ages 6-17 Years

Interventions

DRUG: Placebo
DRUG: LIN Dose A
DRUG: LIN Dose B
DRUG: LIN Dose C
DRUG: LIN 145 µg

Sponsor

Forest Laboratories

Collaborators

[object Object]